Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 8/20 | 0.51 |
| ▸ | NPY1R | P25929 | 7/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.51 |
| ▸ | NPY2R | P49146 | 3/20 | 0.51 |
| ▸ | FURIN | P09958 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181289 | 0.99 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181251 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16502370 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16502368 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181273 | 0.95 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181295 | 0.94 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181294 | 0.93 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181276 | 0.93 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181250 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL16181245 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865865-B2 | N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | NPY4R 638/4885NPY1R 540/4885NPY5R 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.